Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Clearmind Medicine Inc.
< Previous
1
2
Next >
Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug
August 06, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its Groundbreaking Research
July 31, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product
July 19, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism
July 16, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss
July 16, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference
July 12, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment
June 28, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment
June 20, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink
June 11, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
May 10, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment
May 07, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Clearmind Applies to Cease Being a Reporting Issuer in Canada
April 30, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
April 17, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
April 10, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Clearmind Medicine CEO Issues Letter to Shareholders
April 09, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression
March 27, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China
March 19, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial
March 13, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange
March 13, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds
February 27, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
SPRC
Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
February 23, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds
February 20, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
SPRC
Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China
February 05, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center
February 01, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Clearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private Placement
January 16, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Clearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private Placement
January 11, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Clearmind Medicine Completed Type A Meeting with the FDA
January 10, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments
January 04, 2024
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
SPRC
Clearmind Medicine Announces It Is In Compliance with All Applicable Nasdaq Listing Standards
December 14, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
Clearmind Medicine Achieved Positive Results in Cocaine Addiction Treatment
December 05, 2023
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Tickers
CMND
CSE:CMND
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.